showed 19% breast carcinoma with polysomy 17. When we applied 2013 CAP scoring criteria, we found 14.6% increase in number for HER2 amplification with polysomy 17. As we shown one case in Figure 1 , polysomy17 with negative according to CAP 2007 guideline but when we applied 2013 CAP guideline on the same case, the case should be given positive with polysomy. When we re-evaluated the 82 cases that were HER2 nonamplified and polysomy 17 accompanied, we found that 12 (14.6%) cases could be defined as HER2 amplified. These 14.6% patients showed HER2 amplification may be suitable for anti-HER2 targeted therapy. There was a significant increase in the number of HER2 amplified cases, i.e., cases increase from 192 to 246 out of 557 cases. As recent study suggested that the presence of CEP17 alterations could identify a more aggressive subset of breast cancers that are nonresponsive to conventional therapy independently of HER2 amplification status. [7] Some researchers believe that polysomy 17 without HER2 amplification do not predict response to lapatinib in metastatic breast cancer. [7] Conclusion FISH results were evaluated (IHC2+ interpreted according to CAP 2007 guideline) with both 2007 and 2013 ASCO/ CAP scoring criteria, we identified significantly more HER2 positive cases as compared to cases evaluated using the 2007 criteria (P < 0.05). Polysomy of CEP17 is a crucial cause of misinterpretation of HER2 FISH result. Using the 2013 ASCO/ CAP scoring criteria on IHC2+ cases evaluate significantly higher in a number of HER2 amplification with polysomy of chromosome 17, which shows more patients appropriate for targeted treatment. Microsatellite studies on chromosome nine identified acquired uniparental disomy (UPD) as a common defect in MPN. V617F mutation in the Janus kinase 2 gene (JAK2) present in 95% of PV and >50% of essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients. [1] New target gene CBL is associated with aberrations of chromosome 11q. [2] CBL exons 8 and 9 (11q23.3) mutations seen commonly in PMF and post MPN and rarer in PV and ET.
[1] Here we report a case of PV with 11q23 deletion with a stable disease.
(Continue on page 50...)
A 70-year-old male presented with pruritus for 1 year. Hemoglobin was 211 g/L, hematocrit-68.5%, total leucocyte count-20.6 × 10 6 /L, platelet count-470 × 10 9 /L with neutrophilic leukocytosis. Bone marrow was hypercellular with trilineage hyperplasia. Serum erythropoietin was 1.2 mIU/ml and JAK2 V617F from peripheral blood was positive. Cytogenetic analysis showed 46, XY with 11q23 deletion in 100% cells [ Figure 1 ]. He was started on biweekly phlebotomy, aspirin 75 mg once daily and hydroxyurea 500 mg once daily; maintaining a hematocrit of 45% and off phlebotomy for the last 8 months.
Cytogenetic abnormalities in PV being del (20q), del (13q), +8, +9 and chromosome 1 abnormalities and acquired UPD of 1p, 4q 7q, 9p, and 11q associated with homozygosity for mutations in MPL, TET2, EZH2, JAK2 and CBL respectively. [2] CBL mutations in myeloid malignancies are associated with 11q acquired UPD. [3] The present case compared with cases from other studies with chromosome 11 abnormalities in Table 1 . It's apparent from the literature that PV with chromosome 11 abnormalities has a chance of progression to AML. Hence, our index case has to be kept on close follow-up. Next generation sequencing based identification of molecular markers indicating progression, are mostly not available in resource constrain countries like India. Therefore, one may still use conventional cytogenetics to indicate the molecular change responsible for progression.
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